AUSTIN, Texas--(BUSINESS WIRE)--Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has acquired Experimentelle and Diagnostische Immunologie, GmbH, (EDI) in Reutlingen, Germany, an innovative developer of human organotypic (HOT) cell culture test systems. This transaction leverages the strong synergies between EDI’s HOT cultures and RBM’s Multi-Analyte Profiling (MAP) biomarker testing services. Researchers in the pharmaceutical, biotechnology and consumer products industries will benefit from these comprehensive ex vivo biomarker testing platforms, which will help bring safer products to market faster and at a lower cost. Terms of the agreement were not disclosed.
